EFFECTOR Therapeutics, Inc. (NASDAQ:EFTR – Get Free Report)’s stock price traded up 2.4% during mid-day trading on Thursday . The company traded as high as $1.73 and last traded at $1.70. 40,296 shares were traded during trading, a decline of 85% from the average session volume of 275,058 shares. The stock had previously closed at […]
SOLANA BEACH, Calif. and REDWOOD CITY, Calif., May 20, 2024 eFFECTOR Therapeutics, Inc. , a leader in the development of selective translation regulator inhibitors for the treatment of cancer,.
eFFECTOR Therapeutics to Collaborate with the Dana-Farber Cancer Institute on an Investigator-Sponsored Phase 2 Clinical Trial Evaluating Zotatifin as Combination Treatment in ER+ Endometrial Cancer and in Low Grade Serous Ovarian Cancer tmcnet.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from tmcnet.com Daily Mail and Mail on Sunday newspapers.
EFFECTOR Therapeutics Reports First Quarter 2024 Financial Results and Provides Corporate Update marketscreener.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from marketscreener.com Daily Mail and Mail on Sunday newspapers.
eFFECTOR Therapeutics Reports First Quarter 2024 Financial Results and Provides Corporate Update tmcnet.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from tmcnet.com Daily Mail and Mail on Sunday newspapers.